Company Overview of NeuroPhage Pharmaceuticals, Inc.
NeuroPhage Pharmaceuticals, Inc. develops fusion-protein drug candidates or therapies for the treatment of chronic neurodegenerative diseases, amyloidoses, Alzheimer’s and Parkinson’s diseases, multiple orphan indications, and other protein misfolding diseases in patients. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.
222 Third Street
Cambridge, MA 02142
Founded in 2006
Key Executives for NeuroPhage Pharmaceuticals, Inc.
Co-Founder and Chief Executive Officer
President and Chief Operations Officer
Co-Founder, Executive Vice President and Chief Business Officer
Scientific Founder and Scientific Advisor
Senior Vice President of Preclinical Research and Development
Compensation as of Fiscal Year 2014.
NeuroPhage Pharmaceuticals, Inc. Key Developments
NeuroPhage Pharmaceuticals, Inc. Appoints Franz Hefti to President and Chief Operating Officer
Nov 4 14
NeuroPhage Pharmaceuticals, Inc. announced the appointment of Dr. Franz Hefti, PhD, to President and Chief Operating Officer. Dr. Hefti has extensive experience in drug development for neurodegenerative diseases, recently serving as Chief Scientific Officer at Avid Radiopharmaceuticals, now a subsidiary of Eli Lilly, and formerly serving as the Executive Vice President of Drug Development at Rinat Neuroscience, which was acquired by Pfizer.
NeuroPhage Pharmaceuticals, Inc. Presents at Biotech Showcase 2014, Jan-14-2014 08:00 AM
Dec 22 13
NeuroPhage Pharmaceuticals, Inc. Presents at Biotech Showcase 2014, Jan-14-2014 08:00 AM. Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States. Speakers: Jonathan Solomon, Co-Founder, Chief Executive Officer, President and Director.
NeuroPhage Pharmaceuticals, Inc. Wins Second Grant from Michael J. Fox Foundation for Parkinson's Disease Research
Dec 19 13
NeuroPhage Pharmaceuticals, Inc. announced that it has been awarded an $822,000 grant by The Michael J. Fox Foundation for Parkinson's Research (MJFF) for its second-generation drug candidate, NPT088, based on NeuroPhage's GAIM (general amyloid interaction motif) platform, which simultaneously targets multiple misfolded proteins central to many neurodegenerative diseases. In particular, the MJFF grant will be applied to research the effect of NPT088 on alpha-synuclein deposits in the brain, a pathological hallmark of Parkinson's disease (PD). This is NeuroPhage's second grant from MJFF applied to the GAIM platform. The proceeds of the new MJFF grant will be used to test the effect of NPT088 on alpha-synuclein accumulation in the brain in a preclinical model of PD. The preclinical study will be conducted in collaboration with Dr. Eliezer Masliah at the University of California, San Diego. NeuroPhage previously demonstrated that a single treatment of NPT001, a first-generation GAIM molecule, produced significant reductions in neuropathology along with improved motor performance in preclinical PD models. NPT088 is in development for the treatment of conditions characterized by multiple misfolded proteins, with initial focus on PD and Alzheimer's disease (AD). Multiple misfolded proteins are often present in such diseases and can increase disease severity and accelerate disease progression.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 21, 2014